Abstract
High microvessel density, an indirect measure of angiogenesis, has been shown to correlate with increased tumour size, lymph node involvement and poor prognosis in non-small-cell lung cancer (NSCLC). Tumour cell vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PD-ECGF) expression correlate with angiogenesis and a poor outcome in this disease. In a retrospective study VEGF and PD-ECGF expression and microvessel density were evaluated immunohistochemically in surgically resected specimens (T1–3, N0–2) from 223 patients with operable NSCLC using the VG1, P-GF.44C and JC70 monoclonal antibodies respectively. High VEGF immunoreactivity was seen in 104 (46.6%) and PD-ECGF in 72 (32.3%) cases and both were associated with high vascular grade tumours (P = 0.009 and P = 0.05 respectively). Linear regression analysis revealed a weak positive correlation between VEGF and PD-ECGF expression in cancer cells (r = 0.21;P = 0.002). Co-expression of VEGF and PD-ECGF was not associated with a higher microvessel density than VEGF or PD-ECGF only expressing tumours. Furthermore a proportion of high vascular grade tumours expressed neither growth factor. Univariate analysis revealed tumour size, nodal status, microvessel density and VEGF and PD-ECGF expression as significant prognostic factors. Tumour size (P< 0.02) and microvessel density (P< 0.04) remained significant on multivariate analysis. In conclusion, VEGF and PD-ECGF are important angiogenic growth factors and have prognostic significance in NSCLC. Furthermore the study underlines the prognostic significance of microvessel density in operable NSCLC. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Amaya H, Tanigawa N, Lu C, Matsumura M, Shimomatsuya T, Horiuchi T and Muraoka R (1997) Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett 119: 227–235
Apolinario RM, van der Valk P, de Jong JS, Deville W, van Ark-Otte J, Dingemans A-MC, van Mourik JC, Postmus PE, Pinedo HM and Giaccone G (1997) Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularisation in patients with radically resected non-small cell lung cancer. J Clin Oncol 15: 2456–2466
Arenberg DA, Polverini PJ, Kunkel SL, Shanafelt A, Hesselgesser J, Horuk R and Strieter RM (1997) The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J Leukoc Biol 62: 554–562
Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Bergham E, Behr J, Gordon RJ, Osterwalder B and Griffin T (1998) Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 16: 1795–1802
Chandrachud LM, Pendleton N, Chisholm DM, Horan MA and Schor AM (1997) Relationship between vascularity, age and survival in non-small cell lung cancer. Br J Cancer 76: 1367–1375
Ferrara N and Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endoc Rev 18: 4–25
Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, De Laurentiss M, De Placido S, Basolo F, Angeletti CA and Bevilacqua G (1997) Angiogenesis as a prognostic indicator of survival in non-small cell lung carcinoma: a prospective study. J Natl Cancer Inst 89: 881–886
Fontanini G, Boldrini L, Chine S, Pisaturo F, Basolo F, Calcinai A, Lucchi M, Mussi A, Angeletti CA and Bevilacqua G (1999) Expression of vascular endothelial growth factor mRNA in non-small cell lung carcinomas. Br J Cancer 79: 363–369
Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC and Harris AL (1995) Quantification and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count and computer image analysis. J Pathol 177: 275–283
Fox SB, Engels K, Comley M, Whitehouse RM, Turley H, Gatter KC and Harris AL (1997) Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Ann Oncol 8: 271–275
Giatromanolaki A, Koukourakis M, O'Byrne K, Fox S, Whitehouse R, Talbot DC, Harris AL and Gatter K (1996) Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 179: 80–88
Giatromanolaki A, Koukourakis M, Comley M, Kaklamanis L, Turley H, O'Byrne K, Harris AL and Gatter K (1997) Platelet derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer. J Pathol 181: 196–199
Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O'Byrne KJ, Scott PAE, Pezzella F, Georgoulias V, Harris AL and Gatter KC (1998) Vascular endothelial growth factor, wild-type p53 and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 4: 3017–3024
Harris AL (1998) Are angiostatin and endostatin cures for cancer? Commentary. Lancet 351: 1598–1599
Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, Sho M, Nakajima Y, Kanehiro H, Hisanaga M, Nakano H and Miyaka M (1999) Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 79: 1553–1563
Igarashi M, Dhar DK, Kubota H, Yamamoto A, El-Assal O and Nagasue N (1998) The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus. Cancer 82: 1225–1232
Ishikawa F, Miyazono K, Hellman U, Dexler H, Wernstedt C, Hagiwara K, Usuki K, Takaku F, Risau W and Heldin CH (1989) Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 338: 557–562
Jager R, Noll K, Havemann K, Pfluger KH, Knabbe C, Rauvala H and Zugmaier G (1997) Differential expression and biological activity of the heparin-binding growth-associated molecule (HB-GAM) in lung cancer cell lines. Int J Cancer 73: 537–543
Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841–844
Koomagi R and Volm M (1998) Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 79: 19–22
Koukourakis MI, Giatromanolaki A, Kakolyris S, O'Byrne KJ, Apostolikas N, Skarlatos J, Gatter KC and Harris AL (1998) Different pattern of stromal and cancer cell thymidine phosphorylase reactivity in non small cell lung cancer. Impact on tumour neoangiogenesis and survival. Br J Cancer 77: 1696–1703
Lin P, Sanka S, Shan S, Dewhirst MW, Ploverini PJ, Quinn TQ and Peters KG (1998) Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Diff 9: 49–58
Maeda K, Kang SM, Ogawa M, Onoda N, Sawada T, Nakata B, Kato Y, Chung YS and Sowa M (1997) Combined analysis of vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression in gastric carcinoma. Int J Cancer 74: 545–550
Macaulay VM, O'Byrne KJ, Saunders MP, Long L, Gleeson F, Puttick R, Harris AL and Talbot DC (1999) Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 5: 513–520
Moghaddam A and Bicknell R (1992) Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry 31: 12141–12146
Moghaddam A, Zhang HT, Fan TPD, Hu D-E, Lees V, Turley H, Fox SB, Gatter KC, Harris AL and Bicknell R (1995) Thymidine phosphorylase is angiogenic and promotes tumour growth. Proc Natl Acad Sci USA 92: 998–1002
Oshika Y, Nakamura M, Tokunaga T, Ozeki Y, Fukushima Y, Hatanaka H, Abe Y, Yamazaki H, Kijima H, Tamaoki N and Ueyama Y (1998) Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer. Int J Oncol 12: 541–544
Patterson AV, Zhang H, Moghaddam A, Bicknell R, Talbot DC, Stratford IJ and Harris AL (1995) Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer 72: 669–675
Pezzella F, Pastorino U, Tagliabue E, Andreola S, Sozzi G, Gasparini G, Menard S, Gatter KC, Harris AL, Fox S, Buyse M, Pilotti S, Pierotti M and Rilke F (1997) Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 151: 1417–1423
Schor AM, Pazouki S, Morris J, Smither RL, Chandrachud LM and Pendleton N (1998) Heterogeneity in microvascular density in lung tumours: comparison with normal bronchus. Br J Cancer 77: 946–951
Skobe M, Rockwell P, Goldstein N, Vosseler S and Fusenig NE (1997) Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 3: 1222–1227
Takahashi Y, Bucana CD, Akagi Y, Liu W, Cleary KR, Mai M and Ellis LM (1998) Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. Clin Cancer Res 4: 429–434
Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, Yamada Y, Murata F and Aikou T (1996) Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88: 1110–1117
Toi M, Hosina S, Taniguchi T, Yamamoto Y, Ishitsuka H and Tominaga T (1995) Vascular endothelial growth factor and platelet derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res 1: 961–964
Turley H, Scott PAE, Watts VM, Bicknall R, Harris AL and Gatter KC (1998) Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol 186: 313–318
van Zandwijk N and Giaccone G (1996) Treatment of metastatic non-small cell lung cancer. Curr Opin Oncol 8: 120–125
Volm M, Koomagi R and Mattern J (1996) Interrelationships between microvessel density, expression of VEGF and resistance to doxoresistance of non-small-cell lung carcinoma. Anticancer Res 16: 213–218
Whittle C, Gillespie K, Harrison R, Mathieson PW and Harper SJ (1999) Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant. Clin Sci (Colch) 97: 303–312
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
O'Byrne, K., Koukourakis, M., Giatromanolaki, A. et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 82, 1427–1432 (2000). https://doi.org/10.1054/bjoc.1999.1129
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.1999.1129
Keywords
This article is cited by
-
Chitosan-Graft-Poly (N-Isopropylacrylamide)Co-Polymer as a Carrier for Targeted Delivery and Enhanced Catalytic Activity of Capecitabine
Topics in Catalysis (2022)
-
Pulmonary lesions: correlative study of dynamic triple-phase enhanced CT perfusion imaging with tumor angiogenesis and vascular endothelial growth factor expression
BMC Medical Imaging (2021)
-
A model of NSCLC microenvironment predicts optimal receptor targets
Quantitative Biology (2019)
-
Validation of [18F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor
EJNMMI Research (2018)
-
The expansion of targetable biomarkers for CAR T cell therapy
Journal of Experimental & Clinical Cancer Research (2018)
